Navigation Links
Sinovac Reports Unaudited Third Quarter 2009 Financial Results
Date:11/15/2009

BEIJING, Nov. 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2009.

Financial Highlights

  • Sales for the third quarter increased 142% to $21.2 million
  • Sales for the nine-month period increased 40% to $47.8 million
  • Operating income for the third quarter rose 436% to $12.4 million
  • Operating income for the nine-month period increased 90% to $23.7 million.
  • Net income attributable to the shareholders increased 606% to $5.2 million in the third quarter, with diluted EPS of $0.12
  • Cash and cash equivalents at September 30, 2009 was $46.6 million.

Business Highlights

  • In August, Sinovac reported positive top-line results from the completed clinical trial for its internally-developed pandemic influenza A (H1N1) vaccine, PANFLU.1(TM). The analysis of the clinical trial results showed that Sinovac's H1N1 vaccine induces good immunogenicity after one dose. The seropositive rate, seroconvertive rate and GMT increasing multiple conform to international criteria for vaccines, which indicated PANFLU.1 has a good safety and immunogenicity profile.
  • In August, Sinovac was selected by the Beijing Public Health Bureau as one of four manufacturers to supply seasonal influenza vaccine to the citizens of Beijing. The Beijing Public Health Bureau completed the bidding process for the purchase of flu vaccines and corresponding services for 2009 on August 26, 2009. Sinovac will supply its seasonal influenza vaccine, Anflu®, pursuant to this agreement.
  • In September, Sinovac's registration application for its pandemic influenza A (H1N1
    '/>"/>

SOURCE Sinovac Biotech Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
2. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
3. Sinovac to Present at 2009 UBS Global Life Sciences Conference
4. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
5. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
6. Sinovac Obtains Production License for H1N1 Vaccine
7. Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results
8. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
9. Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
10. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
11. Sinovac Adjourns 2008 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 ... technologies such as the Bioruptor® and complete solutions ... system for chromatin immunoprecipitation, alleviating the need for ... and controls needed for ChIP of histones or ...
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... , , -- Phase III ... cancer and non-small cell lung cancer, expected to begin ... strengthens Teva,s oncology offerings with novel therapeutic designed to ... BOTHELL, WA and VANCOUVER, Canada, Dec. 21 /PRNewswire-FirstCall/ - ...
... CHAMPAIGN, Ill. Imagine a polka-dotted postage stamp that can ... colors. As reported in the Sept. 13 issue of ... team at the University of Illinois have developed an artificial ... that is simple, fast and inexpensive and works by ...
... Signatec Inc. today ... The PX1500-4 captures four synchronized channels at sampling rates up to 1.5 GHz, or ... , ... 18, 2009 -- Signatec Inc. today announced the PX1500-4 high-speed digitizer, the most ...
Cached Biology Technology:Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 3Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 4Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 5Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 6Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 7Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 8Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3Signatec Releases PX1500-4, Its 4-Channel, 1.5 GHz Per Channel / 2-Channel, 3 GHz Per Channel PCI-Express Digitizer with Two Virtex-5 FPGAs 2Signatec Releases PX1500-4, Its 4-Channel, 1.5 GHz Per Channel / 2-Channel, 3 GHz Per Channel PCI-Express Digitizer with Two Virtex-5 FPGAs 3Signatec Releases PX1500-4, Its 4-Channel, 1.5 GHz Per Channel / 2-Channel, 3 GHz Per Channel PCI-Express Digitizer with Two Virtex-5 FPGAs 4
(Date:1/22/2015)... YORK and POINT ROBERTS, Washington ... news source covering leading sectors including technology and tech stocks, ... Privacy marketplace featuring master pickpocket and security consultant Apollo ... is stolen and talks about the Wocket™ biometric smart wallet, ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) ... Wearable Technologies Market and Applications, Opportunities, Industry Analysis, ... 2014-2020" report to their offering. , ... can be worn on the user,s body and ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  Since its launch in December ... people to eliminate the pain of trying to remember their ... own biometrics fused to their smartphones. To assist people who ... , the company that created 1U and focuses on redefining ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... HOUSTON -- (June 10, 2010) Most of ... dormant, with just a few producing blood cells and ... invading bacteria can be a call-to-arms, awaking the sleeping ... cells that fight the foreign organisms. The "bugler" that ...
... to most forms of life, and occurs naturally in soil ... exposure to arsenic has been linked to lung, bladder and ... levels or arsenic in drinking water. Chemically similar to phosphorus, ... resembles phosphate (PO 4 3- ). Arsenate interferes with ...
... (KINGSTON, ON.) Queen,s University Brian Amsden is hoping that ... valve will be able to regenerate itself after an injury ... from the University of Western Ontario and University of Toronto, ... rebuild human tissue and speed the healing process. , While ...
Cached Biology News:Gamma interferon a wake-up call for stem cell response to infection 2Gamma interferon a wake-up call for stem cell response to infection 3Arsenic hyperaccumulating ferns: How do they survive? 2Arsenic hyperaccumulating ferns: How do they survive? 3
... a silica based spin filter membrane to isolate ... DNA band is cut from an agarose gel ... The gel slice is melted irreversibly in a ... bound to the silica spin filter membrane and ...
...
... Application: The greater incorporation of Br-dUTP results ... when detected using a fluorescein-labeled anti-BrdU antibody. ... in the kit to counterstain the total ... Br-dUTP, resulting in improved detection than found ...
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
Biology Products: